Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alumis Inc. (ALMS)
USD28.10
-0.21 (-0.74%)
US NASDAQ Healthcare Biotechnology
Address
280 East Grand Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Martin Babler
Website
alumis.com
IPO
2024-06-28
CIK 1847367 ISIN US0223071020
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Acelyrin, Inc. | SLRN | 2025-03-27 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD28.10
-0.21 (-0.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.54
Float Shares
82.71M
Free Float %
67.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93% | +2.84% | +7.60% | -7.20% | +346.20% | +152.36% | +446.12% | +85.19% | +85.19% | +85.19% | +85.19% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
28.10
Low
32.00
+13.9%
Consensus
38.44
+36.8%
Median
37.00
+31.7%
High
50.00
+77.9%
DCF (Unlevered)
1.13
-96.0%
DCF (Levered)
0.49
-98.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 10 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
46.00
+63.7%
|
| Last Year | 10 |
36.60
+30.2%
|
| All Time | 13 |
33.38
+18.8%
|
Quality scores
Altman Z-Score
14.13
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q1'26: -90.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+72.5% ★ Q1'26: +59.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,619.5% Q1'26: -5,011.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,776.3% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,437.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,900.1% Q1'26: +130.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.09× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 17.39M (-100.0%)
|
24.05M
est: 24.26M (-0.9%)
|
8.17M
6.23M – 10.38M
-66.3% YoY
|
30.06M
16.19M – 42.02M
+267.9% YoY
|
169.24M
167.33M – 171.14M
+462.9% YoY
|
426.59M
252.50M – 583.33M
+152.1% YoY
|
875.79M
518.37M – 1.20B
+105.3% YoY
|
| EBITDA |
-297.60M
est: 8.69M (-3,522.9%)
|
-423.71M
est: 12.13M (-3,592.4%)
|
4.09M
3.11M – 5.19M
-66.3% YoY
|
15.03M
8.09M – 21.01M
+267.9% YoY
|
84.62M
83.67M – 85.57M
+462.9% YoY
|
213.30M
126.25M – 291.67M
+152.1% YoY
|
437.89M
259.19M – 598.79M
+105.3% YoY
|
| EBIT |
-300.75M
est: 8.69M (-3,559.1%)
|
-427.20M
est: 12.13M (-3,621.2%)
|
4.09M
3.11M – 5.19M
-66.3% YoY
|
15.03M
8.09M – 21.01M
+267.9% YoY
|
84.62M
83.67M – 85.57M
+462.9% YoY
|
213.30M
126.25M – 291.67M
+152.1% YoY
|
437.89M
259.19M – 598.79M
+105.3% YoY
|
| Net Income |
-294.23M
est: -5.39B (+94.5%)
|
-243.33M
est: -2.43B (+90.0%)
|
-2.67B
-3.08B – -2.25B
-9.9% YoY
|
-2.59B
-3.05B – -2.14B
+2.8% YoY
|
-1.64B
-2.39B – -884.31M
+36.9% YoY
|
-751.66M
-1.11B – -352.88M
+54.1% YoY
|
1.10B
517.35M – 1.63B
+246.6% YoY
|
| SGA |
35.20M
est: 29.65M (+18.7%)
|
91.86M
est: 41.37M (+122.0%)
|
13.93M
10.62M – 17.70M
-66.3% YoY
|
51.25M
27.59M – 71.64M
+267.9% YoY
|
288.52M
285.28M – 291.77M
+462.9% YoY
|
727.27M
430.47M – 994.49M
+152.1% YoY
|
1.49B
883.75M – 2.04B
+105.3% YoY
|
| EPS |
-10.38
est: -6.66 (-56.0%)
|
-2.86
est: -2.86 (+0.1%)
|
-2.94
-3.63 – -2.65
-2.5% YoY
|
-2.88
-3.58 – -2.51
+1.9% YoY
|
-1.92
-2.81 – -1.04
+33.2% YoY
|
-0.88
-1.31 – -0.42
+54.0% YoY
|
1.30
0.61 – 1.92
+246.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-157.82M
OE per share TTM
-1.26
Owner's Yield
-5.12%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
451.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
47
Total invested
125.89M
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B. Tananbaum (“Tananbaum”) | 15.15M | 29.20% | 13.98M | 1.18M | 13.98M | 1.18M | IN | OR PLACE OF ORGANIZATION U.S. Citizen | 2024-07-05 | ↗ |
| 2 | AyurMaya Capital Management Company, LP | 10.65M | 22.57% | — | 10.65M | — | 10.00 | IA, PN | State of Delaware | 2024-07-03 | ↗ |
| 3 | David E. Goel | 10.65M | 22.57% | — | 10.65M | — | 10.00 | HC, IN | United States of America | 2024-07-03 | ↗ |
| 4 | Capital Management V, LLC (“FCM V”) | 5.78M | 11.10% | 5.78M | — | 5.78M | — | OO | — | 2024-07-05 | ↗ |
| 5 | Capital Fund V, L.P. (“Fund V”) | 5.58M | 10.80% | 5.58M | — | 5.58M | — | PN | — | 2024-07-05 | ↗ |
| 6 | Capital Fund VI, L.P. (“Fund VI”) | 4.20M | 8.10% | 4.20M | — | 4.20M | — | PN | — | 2024-07-05 | ↗ |
| 7 | Capital Management VI, LLC (“FCM VI”) | 4.20M | 8.10% | 4.20M | — | 4.20M | — | OO | — | 2024-07-05 | ↗ |
| 8 | Samsara BioCapital GP, LLC | 3.27M | 6.90% | — | 3.27M | — | 10.00 | OO | Delaware | 2024-08-27 | ↗ |
| 9 | Samsara BioCapital, L.P. | 3.27M | 6.90% | — | 3.27M | — | 10.00 | PN | Delaware | 2024-08-27 | ↗ |
| 10 | Srinivas Akkaraju | 3.27M | 6.90% | — | 3.27M | — | 11.00 | IN | — | 2024-08-27 | ↗ |
| 11 | Corey Goodman | 2.83M | 6.30% | — | 2.83M | — | 2.83M | HC, IN | Delaware | 2024-07-11 | ↗ |
| 12 | Robert Adelman | 2.83M | 6.30% | — | 2.83M | — | 2.83M | HC, IN | Delaware | 2024-07-11 | ↗ |
| 13 | venBio Global Strategic Fund IV, L.P. | 2.83M | 6.30% | — | 2.83M | — | 2.83M | PN | Delaware | 2024-07-11 | ↗ |
| 14 | venBio Global Strategic GP IV, LLC | 2.83M | 6.30% | — | 2.83M | — | 2.83M | HC, OO | Delaware | 2024-07-11 | ↗ |
| 15 | Capital Opportunity Fund V, L.P. (“Opportunity Fund V”) | 2.03M | 3.90% | 2.03M | — | 2.03M | — | PN | — | 2024-07-05 | ↗ |
| 16 | Capital Opportunity Management V, LLC (“FCOM V”) | 2.03M | 3.90% | 2.03M | — | 2.03M | — | OO | — | 2024-07-05 | ↗ |
| 17 | Labs Fund I, L.P. (“Labs Fund I”) | 1.96M | 3.80% | 1.96M | — | 1.96M | — | PN | OR PLACE OF ORGANIZATION Delaware | 2024-07-05 | ↗ |
| 18 | Labs Management I, LLC (“FLM I”) | 1.96M | 3.80% | 1.96M | — | 1.96M | — | OO | — | 2024-07-05 | ↗ |
| 19 | Labs Affiliates 2021, LLC (“Labs Affiliates”) | 1.18M | 2.30% | 1.18M | — | 1.18M | — | OO | OR PLACE OF ORGANIZATION Delaware | 2024-07-05 | ↗ |
| 20 | Labs, LLC (“Labs”) | 1.18M | 2.30% | 1.18M | — | 1.18M | — | OO | OR PLACE OF ORGANIZATION Delaware | 2024-07-05 | ↗ |
| 21 | Co-Invest V, LLC (“Labs Co-Invest”) | 194.5K | 0.40% | 194.5K | — | 194.5K | — | OO | — | 2024-07-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
47
-94 vs prev Q
New positions
16
Closed positions
104
Increased
35
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 43.8K +43.8K (+100.0%) | 427.19M +427.2M (+100.0%) | 0.04% +0.042 pp | 0.37% +0.373 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 2 | AYURMAYA CAPITAL MANAGEMENT COMPANY, LP | 15.14M +— (+0.0%) | 147.76M +87.4M (+144.6%) | 14.54% +0.000 pp | 100.00% +0.000 pp | USD9.71 +0.5% | 7 qtrs — |
| 3 | FORESITE CAPITAL MANAGEMENT V, LLC | 5.78M +— (+0.0%) | 56.41M +33.3M (+144.6%) | 5.55% +0.000 pp | 34.31% +13.104 pp | USD12.38 -21.2% | 7 qtrs — |
| 4 | SAMSARA BIOCAPITAL, LLC | 5.76M +955.6K (+19.9%) | 56.19M +37.0M (+193.3%) | 5.53% +0.918 pp | 5.80% +3.296 pp | USD8.48 +15.1% | 6 qtrs — |
| 5 | VENBIO PARTNERS LLC | 4.62M +— (+0.0%) | 45.09M +26.7M (+144.6%) | 4.44% +0.000 pp | 20.85% +10.399 pp | USD8.76 +11.4% | 7 qtrs — |
| 6 | BLACKROCK, INC. | 4.57M +373.4K (+8.9%) | 44.57M +27.8M (+166.4%) | 4.39% +0.359 pp | 0.00% +0.001 pp | USD5.50 +77.5% | 6 qtrs — |
| 7 | FORESITE CAPITAL MANAGEMENT VI LLC | 4.25M +— (+0.0%) | 41.46M +24.5M (+144.6%) | 4.08% +0.000 pp | 12.53% +5.984 pp | USD7.81 +25.0% | 5 qtrs — |
| 8 | VANGUARD GROUP INC | 4.10M +73.7K (+1.8%) | 40.05M +24.0M (+149.1%) | 3.94% +0.071 pp | 0.00% +0.000 pp | USD4.96 +96.8% | 7 qtrs — |
| 9 | CORMORANT ASSET MANAGEMENT, LP | 3.64M +1.5M (+69.3%) | 35.48M +26.9M (+314.1%) | 3.49% +1.430 pp | 1.64% +1.050 pp | USD11.40 -14.4% | 7 qtrs — |
| 10 | SATURN V CAPITAL MANAGEMENT LLC | 3.14M +3.1M (+100.0%) | 30.61M +30.6M (+100.0%) | 3.01% +3.012 pp | 5.62% +5.617 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 11 | NEXTECH INVEST, LTD. | 2.92M +— (+0.0%) | 28.46M +16.8M (+144.6%) | 2.80% +0.000 pp | 2.75% +0.980 pp | USD4.59 +112.6% | 4 qtrs — |
| 12 | OCTAGON CAPITAL ADVISORS LP | 2.53M +2.5M (+100.0%) | 24.70M +24.7M (+100.0%) | 2.43% +2.431 pp | 3.00% +2.999 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 13 | BIOIMPACT CAPITAL LLC | 2.40M +2.4M (+100.0%) | 23.44M +23.4M (+100.0%) | 2.31% +2.307 pp | 2.68% +2.683 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 14 | SR ONE CAPITAL MANAGEMENT, LP | 1.96M +— (+0.0%) | 19.13M +11.3M (+144.6%) | 1.88% +0.000 pp | 2.71% +1.577 pp | USD12.54 -22.2% | 7 qtrs — |
| 15 | BAKER BROS. ADVISORS LP | 1.56M +— (+0.0%) | 15.25M +9.0M (+144.6%) | 1.50% +0.000 pp | 0.09% +0.044 pp | USD12.54 -22.2% | 7 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.49M +94.3K (+6.8%) | 14.52M +9.0M (+161.2%) | 1.43% +0.091 pp | 0.00% +0.001 pp | USD5.46 +78.8% | 6 qtrs — |
| 17 | STATE STREET CORP | 1.26M +157.6K (+14.3%) | 12.29M +7.9M (+179.6%) | 1.21% +0.151 pp | 0.00% +0.000 pp | USD4.77 +104.6% | 6 qtrs — |
| 18 | MILLENNIUM MANAGEMENT LLC | 1.15M +834.1K (+263.1%) | 11.23M +10.0M (+788.2%) | 1.11% +0.801 pp | 0.00% +0.004 pp | USD7.90 +23.5% | 3 qtrs — |
| 19 | ORBIMED ADVISORS LLC | 1.10M -823.7K (-42.8%) | 10.76M +3.1M (+40.0%) | 1.06% -0.791 pp | 0.22% +0.039 pp | USD3.00 +225.3% | 3 qtrs — |
| 20 | TRIUM CAPITAL LLP | 893.1K -2.2M (-71.4%) | 8.72M -3.7M (-30.0%) | 0.86% -2.141 pp | 6.76% +1.893 pp | USD3.15 +209.8% | 3 qtrs — |
| 21 | YU FAN | 789.6K +— (+0.0%) | 7.71M +4.6M (+144.6%) | 0.76% +0.000 pp | 8.35% +4.253 pp | USD12.54 -22.2% | 7 qtrs — |
| 22 | OMEGA FUND MANAGEMENT, LLC | 653.2K +— (+0.0%) | 6.38M +3.8M (+144.6%) | 0.63% +0.000 pp | 2.23% +1.053 pp | USD12.54 -22.2% | 7 qtrs — |
| 23 | OPALEYE MANAGEMENT INC. | 535.0K -130.0K (-19.5%) | 5.22M +2.6M (+96.8%) | 0.51% -0.125 pp | 0.69% +0.314 pp | USD3.00 +225.3% | 3 qtrs — |
| 24 | MORGAN STANLEY | 506.5K +174.1K (+52.4%) | 4.94M +3.6M (+272.7%) | 0.49% +0.167 pp | 0.00% +0.000 pp | USD7.22 +35.2% | 7 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 504.1K +13.1K (+2.7%) | 4.92M +3.0M (+151.1%) | 0.48% +0.013 pp | 0.00% +0.001 pp | USD5.19 +88.1% | 6 qtrs — |
| 26 | SIREN, L.L.C. | 500.0K +500.0K (+100.0%) | 4.88M +4.9M (+100.0%) | 0.48% +0.480 pp | 0.15% +0.146 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 27 | TOWERVIEW LLC | 495.0K +— (+0.0%) | 4.83M +2.9M (+144.6%) | 0.48% +0.000 pp | 3.50% +2.064 pp | USD10.50 -7.0% | 7 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 427.1K +10.0K (+2.4%) | 4.17M +2.5M (+150.5%) | 0.41% +0.010 pp | 0.00% +0.000 pp | USD4.68 +108.5% | 6 qtrs — |
| 29 | INVESCO LTD. | 421.8K +292.3K (+225.6%) | 4.12M +3.6M (+696.4%) | 0.41% +0.281 pp | 0.00% +0.001 pp | USD7.94 +22.9% | 4 qtrs — |
| 30 | NORTHERN TRUST CORP | 418.2K -20.7K (-4.7%) | 4.08M +2.3M (+133.1%) | 0.40% -0.020 pp | 0.00% +0.000 pp | USD5.37 +81.8% | 6 qtrs — |
| 31 | MARSHALL WACE, LLP | 372.9K +372.9K (+100.0%) | 3.64M +3.6M (+100.0%) | 0.36% +0.358 pp | 0.00% +0.003 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 32 | JPMORGAN CHASE & CO | 356.3K +87.7K (+32.6%) | 3.48M +2.4M (+224.4%) | 0.34% -0.009 pp | 0.00% +0.000 pp | USD4.92 +98.4% | 6 qtrs — |
| 33 | TWO SIGMA INVESTMENTS, LP | 298.2K +212.1K (+246.4%) | 2.91M +2.6M (+747.4%) | 0.29% +0.204 pp | 0.00% +0.004 pp | USD8.09 +20.6% | 4 qtrs — |
| 34 | EXOME ASSET MANAGEMENT LLC | 292.3K -520.0 (-0.2%) | 2.85M +1.7M (+144.2%) | 0.28% -0.001 pp | 1.36% +0.657 pp | USD3.99 +144.6% | 2 qtrs — |
| 35 | D. E. SHAW & CO., INC. | 231.7K +231.7K (+100.0%) | 2.26M +2.3M (+100.0%) | 0.22% +0.223 pp | 0.00% +0.001 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 36 | IKARIAN CAPITAL, LLC | 211.1K +211.1K (+100.0%) | 2.06M +2.1M (+100.0%) | 0.20% +0.203 pp | 0.16% +0.161 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 37 | STIFEL FINANCIAL CORP | 209.7K +— (+0.0%) | 2.05M +1.2M (+144.6%) | 0.20% +0.000 pp | 0.00% +0.001 pp | USD6.71 +45.5% | 6 qtrs — |
| 38 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 208.1K -154.5K (-42.6%) | 2.03M +584.4K (+40.4%) | 0.20% -0.148 pp | 0.00% +0.000 pp | USD3.14 +210.8% | 4 qtrs — |
| 39 | JANE STREET GROUP, LLC | 173.8K +146.7K (+541.2%) | 1.70M +1.6M (+1,468.5%) | 0.17% +0.141 pp | 0.00% +0.000 pp | USD8.79 +11.0% | 4 qtrs — |
| 40 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 172.8K +14.0K (+8.8%) | 1.69M +1.1M (+166.2%) | 0.17% +0.014 pp | 0.03% +0.016 pp | USD4.46 +118.8% | 2 qtrs — |
| 41 | NUVEEN, LLC | 169.5K +68.8K (+68.3%) | 1.65M +1.3M (+311.6%) | 0.16% +0.066 pp | 0.00% +0.000 pp | USD6.00 +62.7% | 4 qtrs — |
| 42 | WELLINGTON MANAGEMENT GROUP LLP | 169.1K +3.6K (+2.2%) | 1.65M +990.0K (+149.9%) | 0.16% +0.003 pp | 0.00% +0.000 pp | USD4.11 +137.5% | 2 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 160.1K +23.4K (+17.1%) | 1.56M +1.0M (+186.5%) | 0.15% +0.023 pp | 0.00% +0.000 pp | USD5.78 +68.9% | 6 qtrs — |
| 44 | MARINER, LLC | 145.0K +60.2K (+70.9%) | 1.42M +1.1M (+318.1%) | 0.14% +0.058 pp | 0.00% +0.001 pp | USD6.17 +58.2% | 5 qtrs — |
| 45 | BANK OF AMERICA CORP /DE/ | 138.3K -125.6K (-47.6%) | 1.35M +297.2K (+28.2%) | 0.13% -0.212 pp | 0.00% +0.000 pp | USD4.30 +127.0% | 6 qtrs — |
| 46 | AQR CAPITAL MANAGEMENT LLC | 137.8K -3.1K (-2.2%) | 1.34M +782.6K (+139.2%) | 0.13% -0.003 pp | 0.00% +0.000 pp | USD3.81 +156.2% | 3 qtrs — |
| 47 | QUANTINNO CAPITAL MANAGEMENT LP | 135.4K +47.8K (+54.6%) | 1.32M +972.4K (+278.2%) | 0.13% +0.046 pp | 0.00% +0.002 pp | USD6.03 +61.9% | 2 qtrs — |
| 48 | WELLS FARGO & COMPANY/MN | 129.4K +40.2K (+45.0%) | 1.26M +907.2K (+254.7%) | 0.12% +0.039 pp | 0.00% +0.000 pp | USD6.00 +62.7% | 6 qtrs — |
| 49 | BARCLAYS PLC | 122.2K +103.9K (+565.6%) | 1.19M +996.7K (+508.3%) | 0.12% +0.093 pp | 0.00% +0.000 pp | USD9.04 +8.0% | 6 qtrs — |
| 50 | CITADEL ADVISORS LLC | 119.3K -219.9K (-64.8%) | 1.16M -189.1K (-14.0%) | 0.11% -0.211 pp | 0.00% +0.000 pp | USD3.68 +165.2% | 7 qtrs — |
| 51 | UBS GROUP AG | 114.0K -648.7K (-85.1%) | 1.11M -1.9M (-63.4%) | 0.11% -0.623 pp | 0.00% 0.000 pp | USD3.34 +192.2% | 6 qtrs — |
| 52 | RENAISSANCE TECHNOLOGIES LLC | 108.2K -43.4K (-28.6%) | 1.06M +451.3K (+74.6%) | 0.10% -0.042 pp | 0.00% +0.001 pp | USD3.00 +225.3% | 3 qtrs — |
| 53 | PRELUDE CAPITAL MANAGEMENT, LLC | 87.8K +— (+0.0%) | 857.2K +506.8K (+144.6%) | 0.08% +0.000 pp | 0.06% +0.036 pp | USD4.24 +130.2% | 4 qtrs — |
| 54 | VERITION FUND MANAGEMENT LLC | 80.1K +80.1K (+100.0%) | 781.4K +781.4K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.003 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 55 | LOS ANGELES CAPITAL MANAGEMENT LLC | 163.1K +40.4K (+32.9%) | 760.0K +270.4K (+55.2%) | 0.16% +0.039 pp | 0.00% +0.001 pp | USD4.67 +109.0% | 3 qtrs — |
| 56 | ALLIANCEBERNSTEIN L.P. | 76.6K -4.3K (-5.3%) | 747.6K +424.8K (+131.6%) | 0.07% -0.004 pp | 0.00% +0.000 pp | USD3.00 +225.3% | 3 qtrs — |
| 57 | RHUMBLINE ADVISERS | 69.2K -4.8K (-6.5%) | 675.7K +380.4K (+128.8%) | 0.07% -0.005 pp | 0.00% +0.000 pp | USD4.58 +113.1% | 6 qtrs — |
| 58 | BOOTHBAY FUND MANAGEMENT, LLC | 58.0K +58.0K (+100.0%) | 566.1K +566.1K (+100.0%) | 0.06% +0.056 pp | 0.01% +0.008 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 59 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 56.7K -17.0K (-23.1%) | 553.7K +259.5K (+88.2%) | 0.05% -0.016 pp | 0.01% +0.005 pp | USD3.00 +225.3% | 3 qtrs — |
| 60 | PRICE T ROWE ASSOCIATES INC /MD/ | 50.4K +22.1K (+78.3%) | 493.0K +380.0K (+336.3%) | 0.05% +0.021 pp | 0.00% +0.000 pp | USD5.97 +63.5% | 3 qtrs — |
| 61 | VIRTU FINANCIAL LLC | 50.3K +50.3K (+100.0%) | 491.0K +491.0K (+100.0%) | 0.05% +0.048 pp | 0.02% +0.019 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 62 | BNP PARIBAS ARBITRAGE, SNC | 46.9K +35.1K (+298.3%) | 457.6K +410.6K (+874.4%) | 0.05% +0.034 pp | 0.00% +0.000 pp | USD8.73 +11.8% | 6 qtrs — |
| 63 | DEUTSCHE BANK AG\ | 41.1K +16.4K (+66.2%) | 401.3K +302.6K (+306.6%) | 0.04% +0.016 pp | 0.00% +0.000 pp | USD5.75 +69.7% | 4 qtrs — |
| 64 | LMR PARTNERS LLP | 40.0K -218.4K (-84.5%) | 390.4K -640.8K (-62.1%) | 0.04% -0.210 pp | 0.00% -0.004 pp | USD3.10 +214.8% | 3 qtrs — |
| 65 | CREATIVE PLANNING | 38.1K +38.1K (+100.0%) | 372.0K +372.0K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 66 | TWO SIGMA ADVISERS, LP | 38.1K +4.6K (+13.7%) | 371.6K +238.0K (+178.2%) | 0.04% +0.004 pp | 0.00% +0.001 pp | USD4.69 +108.1% | 2 qtrs — |
| 67 | FOX RUN MANAGEMENT, L.L.C. | 37.7K +37.7K (+100.0%) | 368.0K +368.0K (+100.0%) | 0.04% +0.036 pp | 0.06% +0.057 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 68 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 34.9K +34.9K (+100.0%) | 340.8K +340.8K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.004 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 69 | METLIFE INVESTMENT MANAGEMENT, LLC | 32.5K -110.0 (-0.3%) | 317.0K +187.0K (+143.8%) | 0.03% 0.000 pp | 0.00% +0.001 pp | USD3.99 +144.6% | 2 qtrs — |
| 70 | GRANGE CAPITAL, LLC | 32.0K +32.0K (+100.0%) | 312.3K +312.3K (+100.0%) | 0.03% +0.031 pp | 0.30% +0.300 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 71 | GSA CAPITAL PARTNERS LLP | 30.9K +30.9K (+100.0%) | 302.0K +302.0K (+100.0%) | 0.03% +0.030 pp | 0.03% +0.026 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 72 | INTECH INVESTMENT MANAGEMENT LLC | 29.3K +5.8K (+24.5%) | 286.0K +192.0K (+204.4%) | 0.03% +0.006 pp | 0.00% +0.002 pp | USD4.33 +125.4% | 3 qtrs — |
| 73 | INSCRIPTION CAPITAL, LLC | 26.7K +6.2K (+30.5%) | 260.3K +178.7K (+219.2%) | 0.03% +0.006 pp | 0.03% +0.018 pp | USD5.34 +82.8% | 2 qtrs — |
| 74 | DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 26.6K +26.6K (+100.0%) | 259.0K +259.0K (+100.0%) | 0.03% +0.026 pp | 0.06% +0.059 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 75 | AXQ CAPITAL, LP | 26.4K +7.0K (+35.8%) | 257.8K +180.2K (+232.2%) | 0.03% +0.007 pp | 0.06% +0.028 pp | USD5.51 +77.1% | 2 qtrs — |
| 76 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 26.2K +269.0 (+1.0%) | 256.1K +152.5K (+147.1%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD5.80 +68.3% | 6 qtrs — |
| 77 | XTX TOPCO LTD | 25.0K +343.0 (+1.4%) | 243.6K +145.4K (+148.0%) | 0.02% +0.000 pp | 0.01% +0.001 pp | USD4.07 +139.8% | 5 qtrs — |
| 78 | BALYASNY ASSET MANAGEMENT L.P. | 24.8K +24.8K (+100.0%) | 241.7K +241.7K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD9.76 +0.0% | 3 qtrs — |
| 79 | FMR LLC | 24.0K +17.1K (+246.1%) | 234.1K +206.5K (+746.5%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD8.17 +19.5% | 6 qtrs — |
| 80 | VIRTUS INVESTMENT ADVISERS, INC. | 23.2K +23.2K (+100.0%) | 226.0K +226.0K (+100.0%) | 0.02% +0.022 pp | 0.06% +0.061 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 81 | SCHONFELD STRATEGIC ADVISORS LLC | 23.0K +23.0K (+100.0%) | 224.8K +224.8K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.001 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 82 | BANK OF NOVA SCOTIA | 20.9K +20.9K (+100.0%) | 204.0K +204.0K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 83 | DIMENSIONAL FUND ADVISORS LP | 20.5K +— (+0.0%) | 200.2K +118.4K (+144.6%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.00 +225.3% | 3 qtrs — |
| 84 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 17.7K +318.0 (+1.8%) | 172.4K +103.2K (+149.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.12 +212.8% | 3 qtrs — |
| 85 | IEQ CAPITAL, LLC | 17.4K +690.0 (+4.1%) | 170.0K +103.3K (+154.7%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD4.22 +131.3% | 2 qtrs — |
| 86 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 15.8K -1.1K (-6.7%) | 154.6K +86.8K (+128.2%) | 0.02% -0.001 pp | 0.01% +0.006 pp | USD5.40 +80.7% | 5 qtrs — |
| 87 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 15.3K +— (+0.0%) | 149.7K +88.5K (+144.6%) | 0.01% +0.000 pp | 0.00% +0.001 pp | USD4.43 +120.3% | 5 qtrs — |
| 88 | RUSSELL INVESTMENTS GROUP, LTD. | 15.0K +8.6K (+134.1%) | 146.7K +121.1K (+472.7%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD7.20 +35.6% | 3 qtrs — |
| 89 | MERCER GLOBAL ADVISORS INC /ADV | 14.9K +14.9K (+100.0%) | 145.5K +145.5K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 90 | PROSHARE ADVISORS LLC | 14.6K +1.6K (+12.4%) | 142.8K +90.9K (+175.0%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD3.75 +160.3% | 3 qtrs — |
| 91 | PDT PARTNERS, LLC | 14.6K +14.6K (+100.0%) | 142.1K +142.1K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.009 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 92 | BANCO BTG PACTUAL S.A. | 14.3K +14.3K (+100.0%) | 139.6K +139.6K (+100.0%) | 0.01% +0.014 pp | 0.02% +0.024 pp | USD9.76 +0.0% | 1 qtrs NEW |
| 93 | CITIGROUP INC | 14.1K +10.4K (+283.9%) | 137.3K +122.7K (+839.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD9.43 +3.5% | 6 qtrs — |
| 94 | NEW YORK STATE COMMON RETIREMENT FUND | 11.8K +— (+0.0%) | 114.8K +67.9K (+144.6%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD5.81 +68.0% | 6 qtrs — |
| 95 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 11.2K -155.6K (-93.3%) | 109.3K -556.1K (-83.6%) | 0.01% -0.149 pp | 0.00% -0.006 pp | USD3.73 +161.7% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
1.61
Bullish
Buys
6
Sells
3
Shares acquired
5.41M
Shares disposed
3.37M
Cash buys
—
Cash sales
—
Net activity
+2,041,458
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Tananbaum James B. | Director / 10% Owner | J-Other | A | Common Stock | 1,123,337 | 0.00 | — | 1,123,337 | I | ↗ |
| 2026-04-01 | Foresite Labs, LLC | 10% Owner | J-Other | A | Common Stock | 1,123,337 | 0.00 | — | 1,123,337 | I | ↗ |
| 2026-04-01 | Foresite Capital Management VI LLC | 10% Owner | J-Other | A | Common Stock | 1,123,337 | 0.00 | — | 1,123,337 | I | ↗ |
| 2026-01-26 | Schroer John R. | Officer | A-Award | A | Stock Option (Right to Buy) | 202,225 | 26.31 | 5.32M | 202,225 | D | ↗ |
| 2026-01-26 | Pangali Sanam | Officer | A-Award | A | Stock Option (Right to Buy) | 186,200 | 26.31 | 4.90M | 186,200 | D | ↗ |
| 2026-01-26 | Hardiman Roy C. | Officer | A-Award | A | Stock Option (Right to Buy) | 190,875 | 26.31 | 5.02M | 190,875 | D | ↗ |
| 2026-01-26 | Goldstein David M | Officer | A-Award | A | Stock Option (Right to Buy) | 216,675 | 26.31 | 5.70M | 216,675 | D | ↗ |
| 2026-01-26 | Drappa Jorn | Officer | A-Award | A | Stock Option (Right to Buy) | 221,450 | 26.31 | 5.83M | 221,450 | D | ↗ |
| 2026-01-26 | Bradley Mark Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 190,225 | 26.31 | 5.00M | 190,225 | D | ↗ |
| 2026-01-26 | Babler Martin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 745,875 | 26.31 | 19.62M | 745,875 | D | ↗ |
| 2026-01-09 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 588,235 | 17.00 | 10.00M | 1,853,488 | I | ↗ |
| 2026-01-08 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 117,647 | 17.00 | 2.00M | 5,702,536 | I | ↗ |
| 2026-01-08 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 294,117 | 17.00 | 5.00M | 2,908,332 | I | ↗ |
| 2026-01-08 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 117,647 | 17.00 | 2.00M | 5,702,536 | I | ↗ |
| 2025-12-31 | Goldstein David M | Officer | — | — | Common Stock | 0 | 0.00 | — | 8,994 | I | ↗ |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 51,380 | 10.73 | 551.3K | 1,265,253 | I | ↗ |
| 2025-12-04 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 66,027 | 8.18 | 540.1K | 1,078,876 | I | ↗ |
| 2025-12-03 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 100,000 | 7.75 | 775.0K | 1,012,849 | I | ↗ |
| 2025-12-02 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 96,000 | 7.55 | 724.8K | 912,849 | I | ↗ |
| 2025-12-01 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 86,350 | 7.46 | 644.2K | 816,849 | I | ↗ |
| 2025-11-28 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 38,702 | 7.64 | 295.7K | 730,499 | I | ↗ |
| 2025-11-26 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 48,537 | 7.64 | 370.8K | 691,797 | I | ↗ |
| 2025-11-21 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 72,212 | 7.38 | 532.9K | 2,614,215 | I | ↗ |
| 2025-11-21 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 72,212 | 7.38 | 532.9K | 2,614,215 | I | ↗ |
| 2025-11-21 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 72,212 | 7.38 | 532.9K | 2,614,215 | I | ↗ |
| 2025-11-20 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 125,743 | 7.20 | 905.3K | 643,260 | I | ↗ |
| 2025-11-19 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 190,500 | 6.56 | 1.25M | 2,542,003 | I | ↗ |
| 2025-11-19 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 190,500 | 6.56 | 1.25M | 2,542,003 | I | ↗ |
| 2025-11-19 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 190,500 | 6.56 | 1.25M | 2,542,003 | I | ↗ |
| 2025-11-19 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 137,772 | 6.56 | 903.8K | 517,517 | I | ↗ |
| 2025-11-18 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 117,374 | 6.19 | 726.5K | 2,351,503 | I | ↗ |
| 2025-11-18 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 117,374 | 6.19 | 726.5K | 2,351,503 | I | ↗ |
| 2025-11-18 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 117,374 | 6.19 | 726.5K | 2,351,503 | I | ↗ |
| 2025-11-18 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 102,652 | 6.05 | 621.0K | 379,745 | I | ↗ |
| 2025-11-17 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 150,000 | 5.59 | 838.5K | 2,234,129 | I | ↗ |
| 2025-11-17 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 5.59 | 838.5K | 2,234,129 | I | ↗ |
| 2025-11-17 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 5.59 | 838.5K | 2,234,129 | I | ↗ |
| 2025-11-17 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 914 | 5.51 | 5.0K | 277,093 | I | ↗ |
| 2025-11-13 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 276,179 | 5.25 | 1.45M | 276,179 | I | ↗ |
| 2025-07-30 | Yao Zhengbin | Director | A-Award | A | Stock Option (Right to Buy) | 49,800 | 4.10 | 204.2K | 49,800 | D | ↗ |
| 2025-07-30 | TETRAULT LYNN A. | Director | A-Award | A | Stock Option (Right to Buy) | 49,800 | 4.10 | 204.2K | 49,800 | D | ↗ |
| 2025-07-30 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 49,800 | 4.10 | 204.2K | 49,800 | D | ↗ |
| 2025-07-30 | Machado Patrick | Director | A-Award | A | Stock Option (Right to Buy) | 49,800 | 4.10 | 204.2K | 49,800 | D | ↗ |
| 2025-07-30 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (Right to Buy) | 49,800 | 4.10 | 204.2K | 49,800 | D | ↗ |
| 2025-07-29 | Schroer John R. | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 28,000 | D | ↗ |
| 2025-07-29 | Richardson Derrick | Officer | A-Award | A | Common Stock | 42,800 | 0.00 | — | 42,800 | D | ↗ |
| 2025-07-29 | Pangali Sanam | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 11,111 | D | ↗ |
| 2025-07-29 | Hardiman Roy C. | Officer | A-Award | A | Stock Option (Right to Buy) | 111,950 | 3.95 | 442.2K | 111,950 | D | ↗ |
| 2025-07-29 | Goldstein David M | Officer | A-Award | A | Common Stock | 27,000 | 0.00 | — | 29,115 | D | ↗ |
| 2025-07-29 | Drappa Jorn | Officer | A-Award | A | Common Stock | 25,450 | 0.00 | — | 28,450 | D | ↗ |
| 2025-07-29 | Bradley Mark Christopher | Officer | A-Award | A | Common Stock | 26,750 | 0.00 | — | 48,728 | D | ↗ |
| 2025-07-29 | Babler Martin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 3.95 | 592.5K | 150,000 | D | ↗ |
| 2025-07-10 | Pangali Sanam | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.56 | 356.0K | 100,000 | D | ↗ |
| 2025-07-04 | Pangali Sanam | Officer | — | — | Stock Option (Right to Buy) | 152,400 | 10.29 | 1.57M | 0 | D | ↗ |
| 2025-05-21 | TETRAULT LYNN A. | Director | — | — | Stock Option (Right to Buy) | 21,027 | 9.26 | 194.7K | 0 | D | ↗ |
| 2025-05-21 | Machado Patrick | Director | A-Award | A | Common Stock | 7,064 | 0.00 | 0.07 | 7,064 | I | ↗ |
| 2025-05-21 | AyurMaya Capital Management Company, LP | Director / 10% Owner | A-Award | A | Common Stock, par value $0.0001 per share ("Common Stock") | 4,493,741 | 0.00 | — | 15,139,707 | I | ↗ |
| 2025-05-21 | AKKARAJU SRINIVAS | Director | A-Award | A | Common Stock | 1,214,582 | 0.00 | — | 4,801,370 | I | ↗ |
| 2025-05-06 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 4.34 | 86.8K | 4,247,670 | I | ↗ |
| 2025-05-06 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 4.34 | 86.8K | 4,247,670 | I | ↗ |
| 2025-05-06 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 4.34 | 86.8K | 4,247,670 | I | ↗ |
| 2025-05-05 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 138,368 | 4.58 | 633.7K | 3,564,786 | I | ↗ |
| 2025-05-02 | Tananbaum James B. | Director / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 4.62 | 115.5K | 4,227,670 | I | ↗ |
| 2025-05-02 | Foresite Labs, LLC | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 4.62 | 115.5K | 4,227,670 | I | ↗ |
| 2025-05-02 | Foresite Capital Management VI LLC | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 4.62 | 115.5K | 4,227,670 | I | ↗ |
| 2025-05-02 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 159,920 | 4.55 | 727.6K | 3,426,418 | I | ↗ |
| 2025-04-02 | Colowick Alan | Director | P-Purchase | A | Common Stock | 2,300 | 7.49 | 17.2K | 18,404 | I | ↗ |
| 2025-04-01 | Colowick Alan | Director | P-Purchase | A | Common Stock | 16,104 | 6.97 | 112.3K | 16,104 | I | ↗ |
| 2025-04-01 | Babler Martin | Director / Officer | P-Purchase | A | Common Stock | 15,650 | 6.44 | 100.7K | 106,454 | I | ↗ |
Executive team
Top executives
EBIT / Employee
-19.2K
Shares Outstanding
123.14M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Martin Babler President, Chief Executive Officer and Director | 605.9K | — | — | 9.75M | 306.7K | — | 10.66M | 91.44% | ↗ |
| 2 | 2024 | David Goldstein, Ph.D. Chief Scientific Officer | 466.5K | — | — | 2.59M | 184.9K | — | 3.24M | 79.92% | ↗ |
| 3 | 2024 | Roy Hardiman Chief Business and Strategy Officer | 444.3K | — | — | 2.60M | 175.5K | — | 3.22M | 80.73% | ↗ |
| 4 | 2023 | Martin Babler President, Chief Executive Officer and Director | 516.0K | — | — | 3.89M | 185.8K | — | 4.59M | 84.72% | ↗ |
| 5 | 2023 | David Goldstein, Ph.D. Chief Scientific Officer | 380.0K | — | — | 543.4K | 119.7K | — | 1.04M | 52.09% | ↗ |
| 6 | 2023 | Roy Hardiman Chief Business and Strategy Officer | 380.0K | — | — | 543.4K | 119.7K | — | 1.04M | 52.09% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Babler | President, Chief Executive Officer & Chairman | 1M | male |
| David Goldstein | Chief Scientific Officer | 821.2K | — |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 817.1K | — |
| Roy C. Hardiman | Chief Business & Strategy Officer | 619.8K | male |
| Kolbot By | Senior Vice President & Head of Technical Operations | — | male |
| Mark Bradley | Chief Development Officer | — | male |
| Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | — | male |
| Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | — | female |
| Sanam Pangali | Chief Legal Officer & Corporate Secretary | — | female |
| Grace Halteh | Senior Vice President & Head of Quality and Regulatory | — | female |
| Jack Danilkowicz | Chief Commercial Officer | — | male |
| John R. Schroer | Chief Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALMS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
